Skip to main content
TipRanks
Go Ultimate75% OFF

Transgene (0OCQ) Share Price & Analysis

2 Followers

0OCQ Stock Chart & Stats

€0.72-€0.00(-0.56%)
At close: 4:30 PM GMT
€0.7€0.8€0.9Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
EUR 0.72 - EUR 0.72
52-Week Range
EUR 0.68 - EUR 1.35
Previous Close
EUR 0.72
Volume
N/A
Average Volume (3M)
1,076
Market Cap
EUR 198.97M
Enterprise Value
EUR 108.26M
Total Cash (Recent Filing)
EUR 92.84M
Total Debt (Recent Filing)
EUR 2.18M
Price to Earnings (P/E)
―
Beta
0.12
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage and a large equity base give Transgene more balance-sheet flexibility than its loss profile alone suggests. Limited debt reduces fixed financing pressure and can preserve room to fund clinical development, although continued losses still require careful capital management.

Oncology Pipeline

Transgene has a specialized oncology-immunotherapy focus supported by viral-vector and individualized vaccine approaches. A pipeline spanning multiple solid tumors and combination strategies creates several potential development paths, which can strengthen long-term strategic relevance if clinical programs progress.

Improved Cash Flow

Free cash flow improved about 49% versus 2024, indicating some movement in cash consumption even though it remained negative. If sustained, better cash discipline could extend funding runway and reduce the pace at which external capital is needed.

Bears Say

Persistent Losses

Persistent operating and net losses show that the current cost base is not supported by revenue, while the deeply negative 2025 margins provide no evidence of near-term profitability. This weak earnings foundation can constrain reinvestment and increase dependence on financing.

Revenue Collapse

The sharp 2025 revenue decline and highly volatile historical pattern make the top line an unreliable source of support for ongoing research and development spending. Without a sustainable revenue trajectory, future operating performance remains heavily dependent on successful pipeline progress.

Cash Burn And Funding Risk

Consistently negative operating and free cash flow means Transgene is consuming cash rather than funding development internally. Continued reliance on external capital can reduce financial flexibility and creates ongoing financing or dilution risk while losses persist.

Transgene News

0OCQ FAQ

What was Transgene’s price range in the past 12 months?
Transgene lowest share price was €0.68 and its highest was €1.35 in the past 12 months.
What is Transgene’s market cap?
Transgene’s market cap is €198.97M.
When is Transgene’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Transgene’s earnings last quarter?
Transgene released its earnings results on Sep 24, 2026. The company reported -€0.057 earnings per share for the quarter.
Is Transgene overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Transgene pay dividends?
Transgene pays a dividend of €0.285 which represents an annual dividend yield of ―. See more information on Transgene dividends here
What is Transgene’s EPS estimate?
Transgene’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene have?
Transgene has 278,559,940 shares outstanding.
What happened to Transgene’s price movement after its last earnings report?
Transgene reported an EPS of -€0.057 in its last earnings report. Following the earnings report the stock price went up 1.637%.
Which hedge fund is a major shareholder of Transgene?
Currently, no hedge funds are holding shares in GB:0OCQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology